Alerts will be sent to your verified email
Verify Email
SANJIVIN
|
Sanjivani Paranteral
|
Brooks Laboratories
|
Lyka Labs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Quarterly Sales Volume - Injectables
|
n/a | n/a | n/a |
|
Quarterly Sales Volume - Orals
|
n/a | n/a | n/a |
|
Quarterly Sales Volume - Nutraceuticals
|
n/a | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
-34.5 % | -21.13 % | 62.44 % |
|
5yr average Equity Multiplier
|
-1.07 | 1.68 | 2.9 |
|
5yr Average Asset Turnover Ratio
|
1.28 | 0.62 | 0.73 |
|
5yr Avg Net Profit Margin
|
11.86 % | -21.45 % | -0.79 % |
|
Price to Book
|
5.62 | 2.53 | 2.77 |
|
P/E
|
33.86 | 25.4 | 135.96 |
|
5yr Avg Cash Conversion Cycle
|
9.84 Days | 23.75 Days | 32.55 Days |
|
Inventory Days
|
50.77 Days | 83.11 Days | 24.2 Days |
|
Days Receivable
|
53.66 Days | 80.26 Days | 92.33 Days |
|
Days Payable
|
138.53 Days | 163.46 Days | 106.74 Days |
|
5yr Average Interest Coverage Ratio
|
21.37 | -11.18 | 2.2 |
|
5yr Avg ROCE
|
-90.78 % | -11.18 % | 25.83 % |
|
5yr Avg Operating Profit Margin
|
14.73 % | -10.26 % | 24.02 % |
|
5 yr average Debt to Equity
|
-0.19 | 0.18 | 1.25 |
|
5yr CAGR Net Profit
|
12.42 % | -12.45 % | n/a |
|
5yr Average Return on Assets
|
15.34 % | -13.31 % | 1.72 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
31.2 % | 52.62 % | 58.16 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
3.85 % | -13.79 % | 10.57 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 9.9 % | -3.53 % |
|
Sanjivani Paranteral
|
Brooks Laboratories
|
Lyka Labs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|